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Abstract 28 
Dietary supplementation of nicotinamide adenine dinucleotide (NAD+) precursors has been suggested as a 29 
treatment for non-alcoholic fatty liver disease and obesity. In the liver, NAD+ is primarily generated by 30 
nicotinamide phosphoribosyltransferase (NAMPT), and hepatic levels of NAMPT and NAD+ have been 31 
reported to be dependent on age and body composition. The aim of the present study was to identify time-32 
course-dependent changes in hepatic NAD content and NAD+ salvage capacity in mice challenged with a 33 
high-fat diet (HFD). We fed 7-week-old C57BL/6JBomTac male mice either regular chow or a 60% HFD for 6, 34 
12, 24, and 48 weeks, and we evaluated time course-dependent changes in whole body metabolism, liver 35 
steatosis, and abundance of hepatic NAD-associated metabolites and enzymes. Mice fed a 60% HFD rapidly 36 
accumulated fat and hepatic triglycerides, with associated changes in respiratory exchange ratio (RER) and 37 
a disruption of the circadian feeding pattern. The HFD did not alter hepatic NAD+ levels, but caused a 38 
decrease in NADP+ and NADPH levels. Decreased NADP+ content was not accompanied by alterations in 39 
NAD kinase (NADK) abundance in HFD-fed mice, but NADK levels increased with age regardless of diet. 40 
NAMPT protein abundance did not change with age or diet. HFD consumption caused a severe decrease in 41 
protein lysine malonylation after six weeks, which persisted throughout the experiment. This decrease was 42 
not associated with changes in SIRT5 abundance. In conclusion, hepatic NAD+ salvage capacity is resistant 43 
to long-term HFD feeding, and hepatic lipid accumulation does not compromise the hepatic NAD+ pool in 44 
HFD-challenged C57BL/6JBomTac male mice. 45 
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1. Introduction 53 
In non-alcoholic fatty liver disease (NAFLD) lipids accumulate in the liver without significant alcohol 54 
consumption or viral infection (Angulo, 2002). Reported prevalence varies both with geographic location 55 
and detection method applied for diagnosis. Prevalence in the adult European populations ranges from 56 
20% to 31% (Blachier et al., 2013). NAFLD development associates with obesity and type 2 diabetes, where 57 
prevalence is reported to be as high as 70% (Lazo and Clark, 2008). As the number of obese people is 58 
increasing worldwide, it is estimated that the number of people with NAFLD will follow (Loomba and 59 
Sanyal, 2013). While hepatic steatosis has been described as benign and non-progressive (Yilmaz, 2012), 60 
several studies have reported progression of NAFLD to non-alcoholic steatohepatitis (NASH) and fibrosis 61 
(McPherson et al., 2015; Pais et al., 2013; Wong et al., 2010). NASH can further progress to cirrhosis and 62 
liver cancer (Ekstedt et al., 2006). Simple steatosis can be improved through lifestyle intervention (Shah et 63 
al., 2009), but boosting levels of nicotinamide adenine dinucleotide (NAD+) has also been suggested as a 64 
possible treatment strategy (Gariani et al., 2016). 65 
In the liver, NAD+ can be generated from tryptophan or nicotinic acid (Fukuwatari and Shibata, 2013), but 66 
the majority of NAD+ is generated from nicotinamide, which is converted to nicotinamide mononucleotide 67 
(NMN) in the rate-limiting step mediated by nicotinamide phosphoribosyltransferase (NAMPT), and into 68 
NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1-3) (Verdin, 2015). In rodents, 69 
several studies have demonstrated decreased NAD+ levels and/or NAMPT abundance in the liver following 70 
high-fat diet (HFD) feeding (Choi et al., 2013; Gariani et al., 2016; Uddin et al., 2017; Wang et al., 2017; 71 
Yoshino et al., 2011; Zhang et al., 2014; Zhou et al., 2016). NMN can attenuate HFD-induced phenotypes 72 
and restore NAD+ levels (Yoshino et al., 2011). In several other animal models for obesity, dietary 73 
supplementation with nicotinamide riboside (NR), another NAD+ precursor, prevented hepatic lipid 74 
accumulation, enhanced insulin sensitivity, glucose tolerance, and decreased fat mass accumulation (Canto 75 
et al., 2012; Gariani et al., 2016; Trammell et al., 2016). Additionally, supplementation with NAD+ 76 
precursors has been shown to have substantial anti-aging effects in rodents (Mills et al., 2016; Zhang et al., 77 
2016). NAD+ precursor supplementation is thought to reverse HFD-induced hepatic lipid accumulation 78 
through activation of the sirtuins, a family of deacylase proteins (i.e., SIRT1-7). Sirtuins cleave NAD+ to 79 
nicotinamide and O-acetyl-ADP-ribose and activity can be enhanced by increasing NAD+ levels (Wood et al., 80 
2004). Sirtuins modulate a number of target proteins that regulate glucose and lipid metabolism, 81 
mitochondrial function, and mitochondrial biogenesis (Giblin et al., 2014). Decreased hepatic expression of 82 
SIRT1, SIRT3, SIRT5, and SIRT6 has been reported in patients with NAFLD (Wu et al., 2014). However, liver-83 
specific knockout of SIRT1 and SIRT6 in mice results in hepatic lipid accumulation (Kim et al., 2010; 84 
Purushotham et al., 2009). Consistently, overexpression of SIRT1 protects against HFD-induced obesity 85 
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(Pfluger et al., 2008), and increasing the hepatic NAD pool by inhibition of the NAD-consuming enzymes 86 
poly-ADP ribose polymerases (PARPs) decreases weight gain and hepatic steatosis development by a SIRT1-87 
dependent mechanism in high-fat high-sucrose-fed mice (Gariani et al., 2017). Hence, sufficient sirtuin 88 
activity is important for prevention of hepatic lipid accumulation. It is not known if impaired NAD+ synthesis 89 
or increased NAD+ consumption is responsible for diet-induced impairments in sirtuin activity. Furthermore, 90 
it is not known if insufficient NAD levels and sirtuin activity precede steatosis development in obese 91 
rodents, or if NAD+ depletion arises following hepatic lipid accumulation. In this study, we aimed to 92 
determine the HFD-induced and time-course-dependent changes in hepatic NAD and NAD+ salvage 93 
systems.  94 
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2. Materials and Methods 95 
2.1 Chemicals and Reagents 96 
Unless otherwise noted, all chemicals and reagents were purchased from Sigma Aldrich (Germany). 97 
2.2 Mouse Experiments 98 
Mouse experiments were performed in accordance with the European directive 2010/63/EU of the 99 
European Parliament and of the Council for the protection of animals used for scientific purposes. Ethical 100 
approval was given by the Danish Animal Experiments Inspectorate (#2012-15-2934-307).  101 
2.3 High-fat Diet Time Course Experiment 102 
Sixty-eight male C57BL/6JBomTac (Taconic, Denmark) mice were acquired at 5 weeks of age and were 103 
acclimatized to the animal facility at University of Copenhagen for 2 weeks. The C57BL/6JBomTac strain 104 
was chosen, as these mice do not contain a reported mutation in the nicotinamide nucleotide 105 
transhydrogenase (NNT) gene known to be present in C57BL/6J mice (Toye et al., 2005). Mice were single-106 
housed and distributed into eight groups, matched by lean body mass determined by NMR scanning 107 
(EchoMRI 4-1, EchoMRI, TX, USA). Half of the groups were fed a standard “Chow” diet (Altromin 1319, 108 
Brogaarden, Denmark) containing 13.7 kJ/g, and the other half was fed a 60% HFD containing 21.8 kJ/g 109 
(D12492, Research Diets, NJ, USA). Mice were housed in temperature-controlled conditions (22±1°C) with a 110 
12-hour light/dark cycle (from 6 AM to 6 PM) and feed and water ad libitum. NMR scanning was used to 111 
determine fat mass accumulation and body composition throughout the experiment. For each diet, 112 
separate groups were sacrificed at 6, 12, 24, and 48 weeks of treatment after being subjected to one week 113 
of metabolic chamber measurements. Mice were given 2 days of recovery after the metabolic chamber 114 
measurements before being sacrificed from 1 PM to 5 PM. Mice were sedated using isoflurane and 115 
sacrificed by cardiac puncture. The liver was removed and part of the lobus dexter, lobus sinister, and lobus 116 
caudatus were fixed in 4% PFA solution. Another part of the lobus dexter and lobus sinister were snap-117 
frozen whole in liquid nitrogen for Oil-Red O staining, and the remaining part of the liver was quickly cut 118 
into smaller pieces and snap-frozen in liquid nitrogen. Samples were stored at -80°C and pulverized in liquid 119 
nitrogen prior to analysis.  120 
2.4 Metabolic Chamber Measurements 121 
Prior to the measurements, mice were placed in habituation cages for 6 days, to adapt to the novel 122 
environment. Immediately before being transferred to the habituation cages, mice were fasted for 6 hours 123 
from 8 AM (2 hours in light phase), and blood glucose levels were measured from the tail vein (Contour 124 
Classic glucose meter; Ascensia Diabetes Care Holdings, Switzerland). Following habituation, mice were 125 
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placed in the metabolic chambers for one week (TSE LabMaster, TSE Systems, Germany). Oxygen 126 
consumption, CO2 production, food intake, and water intake were evaluated every 20 min. Data from 4 127 
days of measurement were used to calculate average values for each time point for each mouse. These 128 
values were then used to calculate the average values for each diet/age group for each time point 129 
throughout the light and dark phase.  130 
2.5 Histology and oil-red o staining 131 
Frozen liver tissues were cryo-sectioned (6 µm) and stained with Oil-red O for quantitative and qualitative 132 
lipid analysis. Liver sections were fixed in 4% PFA, embedded in paraffin, cut in 6 µM slices and stained with 133 
hematoxylin/eosin (H&E) (Gebhardt, 1992). For visualization, a Leica DM5000B microscope (Germany) was 134 
used. 135 
2.6 NAD+, NADP+, NADH, and NADPH measurement 136 
NAD+ and NADH levels were determined using an enzymatic cycling assay (Graeff and Lee, 2002). Livers 137 
were processed by lysing 10-20 mg of pulverized tissue in 400 µL of either 0.6 M perchloric acid (for NAD+) 138 
or 0.1 M NaOH (for NADH) with a Tissuelyser II (Qiagen, Hilden, Germany). The NADH extract was incubated 139 
at 70°C for 10 min, and both fractions were centrifuged for 3 min at 13.000 g. The supernatants were 140 
transferred to new tubes. The NAD+ extracts were diluted 1:1600 in 100 mM Na2HPO4 buffer (pH 8) and the 141 
NADH extracts were diluted in 1:500 in 10 mM Tris (pH 6). 100 µL of the diluted extracts were pipetted into 142 
a white 96-well plate, and were added 100 µL reaction mix, containing 100 mM Na2HPO4, 10 µM 143 
flavinmononucleotide, 2% ethanol, 90 U/mL alcohol dehydrogenase, 130 mU/ml diaphorase, 2.5 µg/mL 144 
resazurin and 10 mM nicotinamide. Fluorescence increase (Ex 540 nm/Em 580) was measured over 30 min 145 
and content of each metabolite was calculated from a standard curve and normalized to tissue weight. 146 
NADP+ and NADPH levels were determined from the same extracts, but with a reaction mix containing 100 147 
mM Na2HPO4, 10 µM flavinmononucleotide, 1.2 U/mL glucose 6-phosphate dehydrogenase, 10 mM glucose 148 
6-phosphate, 130 mU/mL diaphorase, 2.5 µg/mL resazurin and 10 mM nicotinamide.  149 
2.7 Metabolomics 150 
Chemicals and reagents: All chemicals and reagents used were of liquid chromatography-mass 151 
spectrometry (LC-MS) grade unless otherwise stated. D5-tryptophan, methanol, water, acetonitrile, 2-152 
propanol, formic acid, ammonium hydroxide were purchased from Sigma Aldrich (Denmark) and 153 
hexakis(2,2-difluoroethoxy)phosphazene from Apollo Scientific (UK). 154 
Metabolites extraction: Samples were randomized for processing and blanks (empty microcentrifuge tubes) 155 
were included in the preparation. Tissues were prepared for metabolomics by weighing off approximately 156 
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50 mg of pulverized liver (exact weight was recorded). Each sample was added 0.5 mL cold 50% methanol 157 
in water (containing 0.008 mg/mL D5-tryptophan for normalization) and were homogenized using a 158 
Tissuelyser II with methanol-washed beads. Each sample was added 0.5 mL chloroform (containing 0.013 159 
mg/mL D35 stearic acid for normalization). Samples were vortexed and incubated for 30 min at 1°C at 160 
highest speed on a Thermomixer Comfort (Eppendorf, Germany). Samples were centrifuged at 0°C for 10 161 
min at 1,500 g. Methanol/water fraction was separated from the chloroform one into new pre-chilled 162 
tubes. Methanol/water extract was centrifuged at 0°C for 10 min at 13,400 g. Supernatants were 163 
transferred to new tubes and after short vortexing 10 µl of each sample was collected to one pre-chilled 164 
microcentrifuge tube, creating a Quality Control sample (QC). Finally, all samples were stored at -80°C until 165 
LC-MS analysis. 166 
LC-MS metabolic profiling: Methanol/water extracts, QC samples and blanks were defrosted on ice, 167 
vortexed and set in a pre-chilled LC-MS vial (Verex Vial, µVial i3 Qsert, Phenomenex) with a screw-cap 168 
(Verex Cert+ MSQ Cap, Phenomenex). Leftover samples were stored at -80°C. Metabolic profiling was 169 
conducted using a LC-MS system: Samples were maintained at 4°C throughout the analysis. QC samples and 170 
blanks were injected after each 5th sample. Chromatographic separation was performed using UHPLC 171 
Dionex Ultimate 3000 (Thermo Scientific, Germany) with Luna Polar C18 column (1.6µm, 2.1x100mm, 172 
Phenomenex, USA) with EVO C18 guard column (sub-2µm, 2.1mm, Phenomenex, USA) kept at 40°C. 173 
Solvent A and B were 0.1% formic acid in acetonitrile and 0.1% formic acid with 5mM ammonium hydroxide 174 
in LC-MS grade water, respectively. A flow rate of 0.3 ml/min was applied with a gradient elution profile: 175 
95% B 0-1 min, 95%-5% B 1.0-10.0 min, 5% B 10.0-12.0 min, 5-95% B 12.0-12.5 min, 95% B 12.5-14-5 min 176 
(equilibration step). LC was coupled with QToF Impact II mass spectrometer (Bruker Daltonics, Germany) 177 
operating in electrospray ionization. Samples were analyzed in positive and negative mode. 5 µl of the 178 
extract was injected in positive mode and 10 µl in the negative mode. Line and profile MS spectra were 179 
acquired in the mass range 50-1000 mass to charge ratio (m/z) at 2.00 Hz spectra rate using the source 180 
settings for positive mode: absolute threshold 50 cts per 1000 sum, End Plate Offset 500V, Capillary 4500V, 181 
Nebulizer 2.0 Bar, Dry Gas 10.0 l/min, Dry Temperature 220°C; Transfer: Funnel 1RF 150.0 Vpp, Funnel 2FR 182 
200.0 Vpp, isCID Eergy 0.0 eV, Hexapole RF 50.0Vpp; Quadrupole: Ion Enegry 4.0 eV, Low Mass 100.0 m/z; 183 
Collision Cell: Collision Energy 7.0 eV, Transfer Time 65.0µs, Collision RF 650.0 Vpp, Pre Pulse Storage 5.0µs. 184 
In negative mode Capillary voltage was set to 3,000 and other parameters were identical as described 185 
above for both modes. MS spectra were divided into 3 segments: pre-analysis 0-0.1 min, calibration 0.1-0.5 186 
min, analysis 0.5-14.5 min. External and internal calibration was based on sodium formate clusters in 2-187 
propanol with Zoom of 1.0% and HPC mode. Additionally, lock-mass calibration based on hexakis(2,2-188 
difluoroethoxy)phosphazene in 2-propanol (0.1 mg/ml) throughout the whole scan was applied. Targeted 189 
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MSMS analysis was performed at the same LC-MS settings as the MS scans with additional collision energy 190 
set to 20 and scan width 1.0 m/z for both negative and positive mode. 191 
LC-MS data analysis: Raw data from the positive and negative mode were automatically calibrated 192 
according to the sodium-clusters and lock-mass shifts throughout the analysis, using the Compass Data 193 
Analysis 4.3 (Bruker Daltonics, Germany). Files were converted to NetCDF format through the Bruker 194 
software and metabolic features were extracted using R-based (Team, 2013) XCMS (Smith et al., 2006), 195 
following CAMERA analysis (Kuhl et al., 2012). Data were normalized according to the internal standard 196 
abundance and samples weight. Statistical analysis was performed using online analytical tools within 197 
MetaboAnalyst 3.0 (Xia and Wishart, 2002). CAMERA-generated buckets were log-transformed and Pareto-198 
scaled. Non-informative variables were removed based on their standard deviation. Initially Principal 199 
Component Analysis was made to visualize the clustering of the samples, QCs and blanks in search for 200 
potential contaminations, machine drifts and outliers. Two-factor independent study using 2-way ANOVA 201 
with False Discovery Rate (FDR) analysis was used to select significantly different metabolic features. 202 
Initially, significantly different metabolic features (P<0.05, FDR corrected) were matched with metabolites 203 
in Human Metabolome Database (Wishart et al., 2013) and Metlin Database (Smith et al., 2005) according 204 
to the mass to charge ratio. Provided at the databases ID numbers for metabolites in Kyoto Encyclopedia of 205 
Genes and Genomes (KEGG) (Kanehisa et al., 2017) were used to perform a batch search in relation to 206 
affected pathways. Following, MSMS profile was acquired for metabolites from significantly affected 207 
metabolic pathways and matched to the MSMS from databases. 208 
2.8 Western Blot Analyses 209 
For Western blot analyses, approximately 20 mg pulverized tissue was homogenized in 500 µL lysis buffer 210 
(pH 7.4, 10% glycerol, 1% IGEPAL, 50 mM Hepes, 150 mM NaCl, 10 mM NaF, 1 mM EDTA, 1 mM EGTA, 20 211 
mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM sodium-pyrophosphate, 5 mM 212 
nicotinamide, 4 μM Thiamet G and protease inhibitors (S8820, SigmaFast)) using a Tissuelyser II (Qiagen, 213 
Germany), 2x30 sec of 30 Hz. Lysates were incubated end-over-end for 45 min at 4°C, and were centrifuged 214 
for 10 min at 16.000 g at 4°C. Protein concentration was determined using the Bicinchoninic Acid Assay 215 
(23227, ThermoFisher Scientific, MA, USA). 20 µg of protein lysate was loaded on acrylamide SDS-page gels 216 
and subject to electrophoresis, together with Precision Plus Protein All Blue Standards and Precision Plus 217 
Protein Dual Color Standards (Bio-Rad, CA, USA) to determine band size. Proteins were then transferred to 218 
polyvinyl difluoride membrane (PVDF, #Ipvh00010, Millipore, Germany) by semi-dry transfer and subjected 219 
to immunoblotting. Membranes were incubated according to the manufacturer’s instructions with the 220 
following antibodies: NAMPT (372A, Bethyl lab, TX, USA), NMNAT1 (45548, Abcam, UK), NMNAT3 (116288, 221 
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Abcam), NRK1 (398852, Santa Cruz, TX, USA), AFMID (19522-1-AP, Proteintech, IL, USA), NAPRT1 (123023, 222 
Abcam), NADK (A304-993A, Bethyl Labs), SIRT1 (07-131, Millipore), SIRT3 (5490, Cell Signaling, MA, USA), 223 
SIRT5 (8782, Cell signaling), SIRT6 (12486, Cell Signaling), PARP1 (9542, Cell Signaling), Acetyl Lysine (9441s, 224 
Cell Signaling), Malonyl Lysine (14942, Cell Signaling). Following wash in TBS-T, membranes were incubated 225 
with HRP-conjugated antibodies, anti-rabbit (170-6515, Biorad, CA, USA) or anti-mouse (170-6516, Biorad) 226 
according to the manufacturer’s instructions. Membranes were developed using a Chemidoc XRS+ (Biorad) 227 
using Lumina Forte Western HRP Substrate (Millipore). Bands were quantified using the Image Lab software 228 
(Bio-Rad) and band intensity was normalized to the band intensity of an internal control of mixed liver 229 
samples loaded twice on all gels. 230 
2.9 Quantitative real-time PCR 231 
Total RNA of liver tissue was extracted by TRIzol® Reagent (Life Technologies) according to manufacturer’s 232 
protocol. 1 µg of total RNA was transcribed into cDNA by M-MLV Reverse Transcriptase (#28025013, 233 
Invitrogen). Quantitative PCR analyses were performed using the qPCR Master Mix Plus Low ROX 234 
(Eurogentec) or Absolute qPCR SYBR Green Low ROX Mix (Thermo Scientific) and the Applied Biosystems 235 
7500 Real Time PCR System. NAMPT mRNA expression (forward: 5’- GAT GGT CTG GAA TAC AAG TTA CAT 236 
GAC T-3’; reverse: 5’-ATG AGC AGA TGC CCC TAT GC-3’, probe: 5’-AGG AGT CTC TTC GCA AGA GAC TGC T-237 
3’) was normalized to Cyclophillin (forward: 5’- ATG TGG TTT TCG GCA AAG TT-3’; reverse: 5’- TGA CAT CCT 238 
TCA GTG GCT TG-3’) 239 
2.10 Statistical Analysis 240 
Data are presented as mean ± SEM. Data were analyzed using 2-way analysis of variance (ANOVA) with 241 
Sidak’s multiple comparison test post hoc. All statistical analysis was performed using Graphpad Prism 6 242 
(Graphpad Software, CA, USA). Statistical significance was defined as p<0.05. */** indicate effects of diet, 243 
p<0.5/0.01, respectively. #/## indicate effects of age, p<0.05/0.01, respectively. 244 
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3. Results 245 
3.1 Six weeks of high-fat diet causes fat mass accumulation, decreased RER, and altered feeding behavior 246 
We first investigated how HFD feeding affects fat mass accumulation and whole-body metabolism over 247 
time. While no change was observed in absolute weight between chow and HFD-fed mice until week 36 248 
(Fig. 1A, p<0.01, n=8), there was a marked difference in body composition early after HFD exposure. In 249 
HFD-fed mice, weight gain was due to rapid fat mass accumulation, which kept increasing throughout the 250 
study (Fig. 1B, p<0.01, n=7-8). In contrast, during the first 12 weeks chow-fed mice showed a larger increase 251 
in lean mass gain compared to the HFD group, which persisted throughout the study (Fig. 1C, p<0.01, n=7-252 
8). 6 weeks of HFD feeding caused major changes in RER and feed intake patterns. Throughout the study, a 253 
circadian pattern in RER was observed in chow-fed mice, with a large increase in RER during the dark phase, 254 
which became smaller with age (Fig. 1D). The HFD-fed mice had only minor circadian RER oscillations at all 255 
4 time-points. Daily food intake patterns were only different between diets at 6 and 12 weeks, where a 256 
significant interaction was observed between diet and time of day (Fig. 1E). At the first two time-points, 257 
chow-fed mice were primarily eating in the dark phase, while HFD-fed mice had a continuous food intake 258 
throughout the dark and light phase. The chow group’s feeding pattern became more irregular after 24 259 
weeks (diet x feeding time interaction effect, p=0.07), and after 48 weeks mice consumed an equal amount 260 
of calories throughout dark and light phase, regardless of diet. Hence, HFD consumption caused major 261 
changes in whole-body metabolism within the first 6 weeks of the study. Fasting blood glucose levels were 262 
not affected by age, and did not differ between chow- and HFD-fed mice (Fig. 1F). Hence, HFD consumption 263 
caused major changes in whole-body metabolism in C57BL6/JBomTac mice within the first 6 weeks of HFD 264 
feeding, but glycemic control did not appear to be affected by the dietary intervention. 265 
3.2 High-fat diet feeding causes progressive accumulation of hepatic triglycerides 266 
To assess if liver steatosis development accompanied the rapidly induced HFD phenotype, we measured 267 
hepatic triglyceride content by oil-red o staining (Fig. 2A). HFD feeding caused a significant increase in 268 
hepatic lipid content after 6 weeks, which became more severe with time (Fig. 2C, p<0.01, n=3). The 269 
presence of steatosis in the HFD-fed groups was also confirmed by H&E staining, which showed visible 270 
steatosis after 24 weeks (Fig. 2B). After 48 weeks, chow-fed mice also had an increased content of lipids 271 
compared to earlier time points (Fig. 2C, p<0.01, n=3). Therefore, while HFD causes rapid accumulation of 272 
hepatic lipids, this did not progress to macrovesicular steatosis until after 24 weeks. Hence, whole-body fat 273 
mass accumulation preceded hepatic macrovesicular steatosis. 274 
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3.3 High-fat diet feeding decreases hepatic NADP(H) content but not NAD+ levels 275 
To assess if hepatic NAD levels were affected by HFD-induced hepatic lipid accumulation, we measured 276 
hepatic NAD+, NADH, NADP+, and NADPH content at all 4 time-points. Hepatic NAD+ levels were not 277 
significantly altered by HFD feeding, but were decreased in the 48-week groups compared to the 24-week 278 
groups (Fig. 3A, P<0.05, n=7-9). NADH levels were not significantly altered, though we observed borderline 279 
effects of both age (p=0.06) and diet (p=0.09) (Fig. 3B, n=7-9). In contrast, we observed a small, but 280 
consistent decrease in NADP levels in all the HFD groups (Fig. 3C, p<0.01, n=7-9). The same was observed 281 
for NADPH (Fig. 3D, p<0.01, n=7-9). LCMS analysis confirmed the HFD-induced decrease in NADP+ (data not 282 
shown) but no other terms associated with NAD metabolism were altered with age or diet. Enrichment 283 
analysis of the metabolomics data suggested changes in purine metabolism. As generation of NAD and 284 
NADP requires ATP (Canto et al., 2015), we quantified levels of ATP-associated metabolites in the liver 285 
samples. Hepatic ATP levels increased during the first 24 weeks of the experiment, and decreased after 48 286 
weeks, regardless of diet (Fig 3E, p<0.01). Levels of adenine, a pre-cursor of ATP (Dudzinska et al., 2010), 287 
decreased slightly with age (Fig. 3F, p<0.05), and levels of hypoxanthine, a deamination product of AMP, 288 
likewise decreased from 6 weeks to 24 weeks (Fig. 3G, p<0.01). This indicates decreased purine catabolism 289 
with age (Maiuolo et al., 2016) that may have caused the increase in hepatic ATP levels. No change was 290 
observed for AMP levels with age, but AMP levels were increased in HFD-fed groups (Fig. 3H). Adenosine 291 
levels oscillated slightly with age (Fig. 3I, main effect of age p<0.05), with a borderline increases after 12 292 
weeks (p=0.07) which decreased after 48 weeks (p=0.07). We observed no enrichment for terms associated 293 
with the pentose phosphate pathways with age or diet (data not shown), suggesting no change in levels or 294 
synthesis of phosphoribosyl pyrophosphate, the co-substrate of NAMPT. However, our analysis revealed a 295 
significant decline in nicotinamide content from 6 to 12 weeks regardless of diet (Fig. 3I, p<0.05), which 296 
persisted throughout the experiment. While there was no significant difference between the 6-week and 297 
48-week groups, we still observed a tendency towards a decrease (p=0.08). This could indicate a decrease 298 
in hepatic NAD turnover or an improvement of NAD+ salvage capability. Thus, the LCMS analysis 299 
demonstrated only minor changes in hepatic NAD metabolism with age and HFD feeding in 300 
C57BL/6JBomTac mice. 301 
3.4 Abundance of NAD+ consuming or -synthesizing enzymes is resistant to HFD feeding 302 
Aging in mice has been reported to cause a shift in hepatic NAD+ salvage pathways, with a decreased 303 
abundance of NAMPT and an increased abundance of NMNATs and enzymes involved with de novo 304 
synthesis of NAD (Zhou et al., 2016). As HFD feeding has also been reported to affect mRNA levels of NAD+ 305 
salvage pathway enzymes (Drew et al., 2016), we investigated if protein abundance of these enzymes were 306 
altered by age and/or diet. NAMPT protein abundance was not affected by age or diet (Fig. 4A), but Nampt 307 
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mRNA levels increased with age regardless of diet, indicating that more Nampt mRNA is required to 308 
maintain NAMPT protein abundance (Fig. 4B, p<0.01, n=8). NMNAT1 abundance increased after 24 weeks 309 
and 48 weeks regardless of diet (Fig. 4C, p<0.01, n=7-9), but was significantly increased in HFD-fed 310 
compared to chow-fed animals (p<0.05). In contrast, NMNAT3 abundance was decreased in HFD-fed 311 
animals (Fig. 4D, main effect p<0.05, n=7-9) but did not change with age. This could indicate an increased 312 
demand for NAD in the nucleus where NMNAT1 is localized, with a corresponding decreased demand for 313 
NAD in the mitochondria where NMNAT3 is localized. Nicotinamide riboside kinase 1 (NRK1) abundance 314 
was increased after 48 weeks compared to the 6-week time-point (Fig. 4E, p<0.01, n=7-9) but was not 315 
affected by diet. Abundance of Arylformamidase (AFMID), an essential enzyme in the generation of NAD 316 
from tryptophan, was not significantly affected by either diet or age (Fig. 4F). NAPRT1, which converts 317 
nicotinic acid to nicotinic acid mononucleotide was not altered by diet or age (Fig. 4G, n=7-9). As HFD 318 
caused a decrease in NADP(H) levels, we measured abundance of NAD kinase (NADK) (Verdin, 2015). NADK 319 
levels were not affected by HFD, but increased with age in both diet groups (Fig. 4H, p<0.01, n=7-9). While 320 
the abundance of NAD synthesizing enzymes were not dramatically affected by HFD feeding, we 321 
hypothesized that NAD consuming enzymes could be affected. HFD feeding or aging did not affect protein 322 
abundance of SIRT1, SIRT3, SIRT5, or SIRT6 (Fig. 4I-L). In contrast, PARP1 abundance was slightly elevated in 323 
HFD-fed mice (Fig. 4M, p<0.05, n=7-9). To evaluate if endogenous sirtuin activity was altered, we 324 
determined two sirtuin-regulated post-translational modifications of lysine residues, acetylation (Fig. 5A) 325 
and malonylation (Fig. 5B) (Du et al., 2011; Giblin et al., 2014). A tendency towards decreased acetylation 326 
following HFD feeding was observed (Fig. 5A, p=0.09), as was a tendency towards decreased lysine 327 
acetylation with age (Fig. 5A, p=0.05). In contrast, HFD-feeding resulted in decreased global lysine 328 
malonylation of multiple bands from 6 weeks of HFD-feeding (Fig. 5B, p<0.05). This change persisted 329 
throughout the experiment. Hence, while HFD feeding only cause minor changes to NAD-associated 330 
metabolites and proteins, lysine malonylation is rapidly affected by HFD consumption. 331 
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4. Discussion 332 
The relationship between NAMPT/NAD+ levels and NAFLD development is incompletely known. Data 333 
obtained from humans are inconclusive with one study reporting decreased Nampt mRNA expression in the 334 
liver of NAFLD patients compared to healthy controls (Dahl et al., 2010), whereas another study reported 335 
increased hepatic Nampt mRNA levels in morbidly obese patients compared to lean controls (Auguet et al., 336 
2013). To understand how obesity and hepatic lipid accumulation affect NAD metabolism and the hepatic 337 
NAD+ salvage pathway, we performed a HFD time-course study for 48 weeks in C57BL/6JBomTac mice. 338 
While the decreased lean mass in the HFD-fed groups was surprising, the increased fat mass accumulation, 339 
changes in RER, and altered feeding behavior are well-characterized effects of HFD feeding (Kohsaka et al., 340 
2007; Williams et al., 2014). We found that mice accumulated a large amount of fat mass and hepatic 341 
triglycerides, which was associated with decreased hepatic content of NADP+ and NADPH as previously 342 
reported (Trammell et al., 2016). The decreased NADP+ levels were not accompanied by a decrease in NADK 343 
abundance. However, NADK abundance increased with age regardless of diet, which may reflect higher 344 
demands for NADP with age. 345 
HFD consumption did not severely affect hepatic NAD+ levels, the abundance of NAD+ producing enzymes, 346 
or sirtuin protein levels. This is in contrast to several previous studies, which have described decreased 347 
NAMPT and/or NAD+ levels in the liver of obese rodents (Choi et al., 2013; Gariani et al., 2016; Uddin et al., 348 
2017; Wang et al., 2017; Yoshino et al., 2011; Zhang et al., 2014; Zhou et al., 2016). Moreover, we have 349 
previously reported elevated hepatic NAD+ levels in HFD-fed mice (Penke et al., 2015), and levels of Nampt 350 
mRNA were increased and NAD+ unaltered in mice fed a 60% HFD from 3 days to 16 weeks (Drew et al., 351 
2016). While most of the studies compare HFD-fed animals to animals fed an unmatched chow diet, two 352 
studies used a matched low-fat diet to ensure comparable micronutrient composition of the diets (Wang et 353 
al., 2017; Zhang et al., 2014). Thus, one explanation for the discrepancies in the reported responses to HFD 354 
feeding may be related to the level of NAD+ precursors in the diets. However, the levels of NAD+ precursors 355 
in the diets used in the present study do not appear to explain the inconsistent findings. While none of the 356 
diets contained nicotinamide, nicotinic acid content was 63 µg/g diet in chow vs. 30 µg/g diet in the HFD. 357 
Moreover, tryptophan levels were 2.9 mg/g diet in the chow diet, but tryptophan content of the HFD was 358 
not reported by the manufacturer. Tryptophan content in the HFD can, however, be estimated to 3.2 mg/g, 359 
as this diet contained 258.4 g casein pr. kg, with an estimated tryptophan content of 12.5 mg/g protein 360 
(Bendtsen et al., 2014).  361 
Differences between studies could result from different methods of assessing NAD+ content. However, 362 
studies obtaining different results have used similar methodologies to determine NAD+ levels. For instance, 363 
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commercial kits were used in some studies (Choi et al., 2013; Drew et al., 2016; Wang et al., 2017; Zhou et 364 
al., 2016), while other studies used mass spectrometry (Gariani et al., 2016), HPLC (Penke et al., 2015; 365 
Yoshino et al., 2011), or a cycling assay (Uddin et al., 2017) similar to the assay applied in the present study. 366 
Thus, results appear not to be associated with a particular method for NAD+ detection. 367 
Differences between observed changes in NAD+ in response to dietary interventions could potentially be 368 
due to the specific mouse strains used and how well glycemic control is maintained. Perturbed whole body 369 
glucose metabolism may affect the hepatic NAD+ pool more than obesity. For instance, a ~20% decrease in 370 
hepatic NAD+ was observed after 20 weeks of 60% HFD feeding, but this was further reduced to 50% when 371 
these mice were treated with streptozotocin to induce diabetes (Trammell et al., 2016). We used 372 
C57BL6/JBomTac mice that were able to maintain glycemic control throughout the study. Interestingly, the 373 
C57BL6/JBomTac mice have recently been demonstrated to have a deletion in the Y-chromosome that 374 
confers decreased fertility (MacBride et al., 2017). However, whether this deletion plays any role in 375 
maintaining NAD+ levels in C57BL/6JBomTac mice on a HFD has not been investigated. 376 
A mutation in the Nnt gene in C57BL/6J was demonstrated to contribute to the impaired glucose tolerance 377 
observed in this strain (Toye et al., 2005). The majority of studies demonstrating decreased NAD+ levels in 378 
the liver of HFD-fed animals have been conducted in C57BL/6J (Gariani et al., 2016; Uddin et al., 2017; Zhou 379 
et al., 2016). Studies reporting no changes or increases in hepatic NAD+ content after HFD feeding, 380 
however, were performed in C57BL/6 mice without the Nnt mutation (Drew et al., 2016; Penke et al., 2015; 381 
Williams et al., 2014). Thus, it is possible that the mutation in Nnt contributes to the decrease in NAD+ 382 
levels in HFD-fed C57BL/6J mice. It should be noted that decreased NAD+ levels in response to a HFD are 383 
not limited to C57BL/6J mice. Decreased NAD+ levels following HFD have been observed in in ICR mice 384 
(Wang et al., 2017; Zhang et al., 2014) and BALB/C mice (Choi et al., 2013). 385 
A final source of variation between studies could be time of sacrifice, as NAD+ levels and Nampt mRNA 386 
levels oscillate (Ramsey et al., 2009). However, as most reports do not state the time of sacrifice, it is not 387 
possible to assess if time of sacrifice is an important factor in this context.  388 
NAMPT protein abundance in the liver was unaffected by HFD consumption in our study. In contrast to 389 
NAMPT, NMNAT1 abundance was slightly increased in HFD-fed mice, and NMNAT3 abundance was 390 
decreased. Another study reported increased Nmnat1 mRNA levels and decreased NMNAT3 protein 391 
abundance in the first week of HFD feeding, but this was normalized after 3 weeks (Drew et al., 2016). 392 
NMNAT1 levels generally increased with age, which was also the case for NRK1. NRK1 is essential in 393 
processing NR, but is also important for utilizing NMN (Ratajczak et al., 2016). The increased abundance of 394 
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these two enzymes may suggest an increased demand for NAD+ with age. PARP1 abundance increased 395 
slightly with HFD, which was also previously observed for mRNA levels (Drew et al., 2016). On the other 396 
hand, none of the investigated sirtuins changed in abundance with age or diet. Thus, while hepatic 397 
knockout of SIRT1 and SIRT6 causes steatosis (Kim et al., 2010; Purushotham et al., 2009), HFD-induced 398 
hepatic steatosis per se does not affect the abundance of these proteins. We cannot rule out that 399 
endogenous sirtuin activity is affected, as mice fed a 45% HFD for 16 weeks had decreased hepatic SIRT3 400 
activity, but unaltered SIRT3 abundance (Kendrick et al., 2011). The effects of HDF feeding on hepatic SIRT3 401 
abundance is unclear, as another study reported decreased SIRT3 abundance after HFD feeding (Hirschey et 402 
al., 2011). This study also reported hepatic hyperacetylation following chronic HFD feeding, which was not 403 
observed in our study. In contrast, malonyl-lysine band intensity was reduced in HFD-fed mice after 6 404 
weeks, which persisted throughout the experiment. Lysine residues are demalonylated by SIRT5 (Du et al., 405 
2011), but SIRT5 abundance was unaltered between chow-fed and HFD-fed mice in our study, indicating 406 
either increased SIRT5 activity or decreased addition of malonyl to lysine targets. SIRT5 regulates a range of 407 
important processes in the liver, such as the urea cycle, ketogenesis and β-oxidation. Mice fed a 60% HFD 408 
for 16 weeks have increased malonyl-CoA levels compared to LFD-fed mice (Go et al., 2016), which could 409 
suggest that malonyl-CoA accumulates, even though altered malonyl-CoA levels were not observed in our 410 
LCMS analysis. Malonyl-CoA is an important metabolite for regulating fatty-acid oxidation and synthesis 411 
(Saggerson, 2008). A previous study investigated the malonylome by proteomic analysis, and found that 412 
72% of the identified malonylated proteins were involved in metabolism, especially glucose metabolism (Du 413 
et al., 2015). It is currently not known how malonylation affects protein activity, although site-specific 414 
malonylation of fructose bisphosphate aldolase B (ALDOB) decrease the enzymatic activity (Du et al., 2015). 415 
Decreased protein malonylation may therefore represent an early adaptation to a fat-based metabolism. 416 
However, the significance of malonylation for adapting to HFD-feeding remains undetermined.  417 
In conclusion, we find that hepatic lipid accumulation in response to prolonged HFD feeding in 418 
C57BL/6JBomTac mice does not affect the hepatic NAD pool or compromise the hepatic NAD+ salvage 419 
pathway. While HFD causes major changes to whole body metabolism, the liver NAD+ salvage system is 420 
resilient, even in the presence of macrovesicular steatosis. HFD causes minor changes in the abundance of 421 
NMNAT1, NMNAT3, PARP1, NADP+, and NADPH, but not NAMPT or NAD+. As HFD feeding per se does not 422 
appear to affect the function of the NAD+ salvage pathway, the decreased NAD+ salvage pathway function 423 
reported in other studies could be mediated by other factors than hepatic lipid accumulation.   424 
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Legends 623 
Figure 1: High-fat diet feeding causes mice to rapidly accumulate fat mass, decrease RER and affect their 624 
circadian feeding pattern 625 
Mice were fed a 60% HFD for 48 weeks. Throughout the experiment, (A) total body weight, (B) fat mass, 626 
and (C) lean mass were measured. Prior to each sacrifice point, mice were monitored in metabolic 627 
chambers. Graphs show pooled averages for the first 4 days of measurements. Grey area indicates dark 628 
phase and white area indicates light phase. Graphs show (D) average RER and (E) Food intake in kJ, after 6, 629 
12, 24, and 48 weeks of either chow (black) or HFD-consumption (red). */** indicate effects of diet, 630 
p<0.5/0.01, respectively. #/## indicate effects of age, p<0.05/0.01, respectively. n=7-8 per group per time 631 
point. 632 
Figure 2: High-fat diet feeding causes hepatic lipid accumulation  633 
Livers were oil-red o stained to evaluate hepatic lipid accumulation. (A) Representative images for each 634 
time-point were selected for the figure. (B) To assess hepatic steatosis development, livers were subject to 635 
H&E staining. Representative images from each time point are displayed. (C) Staining intensity of the oil-red 636 
O sections was used to quantify hepatic lipid content (n=3 per group per time point). */** indicate effects 637 
of diet, p<0.5/0.01, respectively. #/## indicate effects of age, p<0.05/0.01, respectively.  638 
Figure 3: High-fat diet feeding decreased hepatic NADP and NADPH levels without affecting NAD content 639 
To investigate how high-fat diet feeding affects the hepatic NAD pool, we measured liver (A) NAD+ levels 640 
and (B) NADH levels. We also measured (C) NADP+ levels and (F) NADPH levels. Using MSMS we measured 641 
abundance of (D) ATP, (E) Adenine, (F) Hypoxanthine, (G) AMP, (G) Adenosine, and (I) nicotinamide. */** 642 
indicate effects of diet, p<0.5/0.01, respectively. #/## indicate effects of age, p<0.05/0.01, respectively. 643 
n=7-9 per group per time point. 644 
Figure 4: High-fat diet feeding alters NMNAT abundance but does not significantly affect abundance of 645 
NAD synthesizing or NAD consuming enzymes 646 
To investigate how HFD-feeding and aging affected the proteins involved in NAD+ salvage, we measured 647 
hepatic (A) NAMPT protein abundance, (B) Nampt mRNA levels, (C) NMNAT1 protein abundance, (D) 648 
NMNAT3 protein abundance, (E) NRK1 protein abundance, (F) AFMID protein abundance, (G) NAPRT1 649 
protein abundance, and (H) NADK protein abundance. We also measured the abundance of (I) SIRT1, (J) 650 
SIRT3, (K) SIRT5, (L) SIRT6, and (M) PARP1. */** indicate effects of diet, p<0.5/0.01, respectively. #/## 651 
indicate effects of age, p<0.05/0.01, respectively. n=7-9 per group per time point. 652 
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Figure 5: High-fat diet feeding causes decreased global lysine malonylation 653 
To evaluate how sirtuin-regulated lysine modifications were affected by HFD consumption and aging, (A) 654 
global lysine acetylation and (B) global lysine-malonylation were measured by Western blot analyses. Lane 655 
intensity was quantified and used to determine effects of age or diet on lysine acetyl/malonylation. */** 656 
indicate effects of diet, p<0.5/0.01, respectively. #/## indicate effects of age, p<0.05/0.01, respectively. 657 
n=7-9 per group per time point. 658 
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